1 tablet contains 50 mg of furazidine (Furazidinum).
Excipient of known effect: 14 mg of sucrose in a tablet.
The drug is recommended in the treatment of acute and recurring uncomplicated lower urinary tract infections.
Hypersensitivity to the active substance, nitrofuran derivatives, or any of the excipients.
1st trimester of pregnancy.
Period of full-term pregnancy (from 38th week) and labour, due to the risk of haemolytic anaemia in the neonate.
Children and youth under 15 years of age.
Kidney failure (creatinine clearance below 60ml/min or increased serum creatinine level).
Diagnosed polyneuropathy, e.g. diabetic.
Glucose-6-phosphate dehydrogenase deficiency.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
1 tablet contains 50 mg of furazidine (Furazidinum).
Excipient of known effect: 14 mg of sucrose in a tablet.
The drug is recommended in the treatment of acute and recurring uncomplicated lower urinary tract infections.
Hypersensitivity to the active substance, nitrofuran derivatives, or any of the excipients.
1st trimester of pregnancy.
Period of full-term pregnancy (from 38th week) and labour, due to the risk of haemolytic anaemia in the neonate.
Children and youth under 15 years of age.
Kidney failure (creatinine clearance below 60ml/min or increased serum creatinine level).
Diagnosed polyneuropathy, e.g. diabetic.
Glucose-6-phosphate dehydrogenase deficiency.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
